ClinicalTrials.gg
TerminatedNCT05260008SPARKUpdated Aug 14, 2025Results posted

Study Assessing Pain Relief After Replacement of the Knee

A Phase 2 interventional study of ATX-101 and ATX-101 in Acute Postoperative Pain, sponsored by Allay Therapeutics, Inc.. Terminated at 13 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Allay Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Based on positive data from the dose-ranging portion of the study, Sponsor decided as of May 28, 2024 not to move forward with the previously designed global ATX101-TKA-003 study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Pain, Postoperative with a site in United Kingdom — 6 open to participants now, 6 under way, 1 of them phase 3. Pain, Postoperative · United Kingdom.

Enrollment
17th of 40
112 · median 100
Started
2022
with 3 others
Phase 2
6 of 51
none open now
Registered
43rd of 51
by date
Lead sponsor
1 of 51
Allay Therapeutics, Inc.

Among the 51 studies in Pain, Postoperative with a site in United Kingdom, this one is the 17th largest by enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2022, is one of 6 in phase 2, and was the 43rd registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

6 of the 51 studies in Pain, Postoperative with a site in United Kingdom are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Pain, Postoperative with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a Phase 2B randomized, double blind, active controlled, multi-center clinical trial to evaluate the safety and efficacy of ATX-101 in participants following total knee arthroplasty. The following is short title and acronym for the study: Study Assessing Pain Relief after Replacement of the Knee (SPARK)

03

Conditions studied

  • Acute Postoperative Pain

Browse trials for

Keywords

  • postoperative pain
  • post-surgical pain total knee arthroplasty
  • total knee replacement ATX-101
  • bupivacaine
  • bupivacaine implant
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary indication of total knee arthroplasty is knee pain due to osteoarthritis or post-traumatic arthritis.
  • Scheduled to undergo primary unilateral total knee arthroplasty with a cemented prosthesis, without use of a surgical drain, and under bupivacaine spinal anesthesia (dextrose is permitted).
  • American Society of Anesthesiology (ASA) Physical Classification System of class 1, 2 or 3.

Exclusion criteria

Exclusion Criteria:

  • Has a planned concurrent surgical procedure.
  • Has had any previous arthroplasty, unicompartmental knee arthroplasty or total knee arthroplasty in the study knee or previous arthroplasty, unicompartmental knee arthroplasty, or total knee arthroplasty in the contralateral knee within 6 months prior to screening.
  • Has been administered any type of intra-articular injection within 3 months of surgery in the trial knee.
  • or has a known history of , (HIV), or .
  • Routinely take opioid analgesics and are expected to require opioid analgesics in the postsurgical period that is not strictly related to the trial.
  • Unable to abstain from opioid use for knee pain within 14 days of surgery.
  • Has been administered systemic within 14 days prior to surgery.
  • Has been administered any local anesthetic within 5 days prior to the scheduled surgery.
  • Screening (ECG) with significant abnormalities associated with significant heart disease.
  • Has a or a known suspected history of allergy, or idiosyncratic reaction to trial medications.
  • Has uncontrolled depression, anxiety, psychiatric, or neurological disorder that might interfere with trial study assessments.
  • Has a medical condition or receiving medication such that, in the opinion of the investigator, participating in the trial would pose a health risk to the subject or might interfere with the study outcome.
  • Has a known or suspected history of drug or alcohol abuse. A subject with a history of alcohol use disorder that has ≥10 years sobriety will be permitted.
  • Has received/used an drug, product, or device for a clinical trial within 30 days of screening. COVID-19 vaccines are permitted if the subject is not in a clinical trial for the vaccine.
  • Has a (BMI) ≥45 kg/m2
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    ATX-101 Dose A

    ATX-101 Dose A

    Drug: ATX-101

  • Experimental
    ATX-101 Dose B

    ATX-101 Dose B

    Drug: ATX-101

  • Active comparator
    bupivacaine hydrochloride

    bupivacaine hydrochloride without epinephrine via local infiltration and/or nerve block

    Drug: bupivacaine hydrochloride without epinephrine

Interventions

  • ATX-101 (bupivacaine) implant, one-time administration into the surgical site

  • ATX-101 (bupivacaine) implant, one-time administration into the surgical site

  • Drugbupivacaine hydrochloride without epinephrine

    bupivacaine hydrochloride (125 mg) without epinephrine via local infiltration and/or nerve block

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) for the Numeric Rating Scale at Rest (NRS-R) of Pain Intensity.

    NRS-R for pain intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).

    Time frame: from 30 minutes post-surgery through hour 168 (Day 8)

Secondary outcomes

  1. Percentage of Subject Who Remain Opioid Free.

    Opioid free is defined as no opioid rescue medication was recorded for the timepoint displayed and onwards.

    Time frame: Surgical Closure to Day 30

  2. Total Post-surgical Use of Rescue Opioid Medications.

    Total post-surgical use of rescue opioid medications (days).

    Time frame: Surgical Closure to Day 30, Opioid consumption is summarized descriptively every 24-hour period through Day 30

  3. Time to First Rescue Opioid Medication.

    Time to first postsurgical use of rescue opioid medication (days).

    Time frame: Surgical Closure to Day 30

07

Results

Posted Aug 14, 2025

Participant flow

Participant flow — Overall Study
MilestoneATX-101 1000 mgATX-101 1500 mgBupivacaine HydrochlorideSaline Placebo
Started3737344
Completed3736344
Not completed0100
Withdrew: Physician decision0100

Outcome measures

PrimaryArea Under the Curve (AUC) for the Numeric Rating Scale at Rest (NRS-R) of Pain Intensity.

NRS-R for pain intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).

Time frame:
from 30 minutes post-surgery through hour 168 (Day 8)
Reported as:
Mean · pain intensity score*hour
Area Under the Curve (AUC) for the Numeric Rating Scale at Rest (NRS-R) of Pain Intensity.
pain intensity score*hourATX-101 1000 mgATX-101 1500 mgBupivacaine HydrochlorideSaline Placebo
Area Under the Curve (AUC) for the Numeric Rating Scale at Rest (NRS-R) of Pain Intensity.517.32 ± 284.675518.03 ± 239.299595.26 ± 258.945756.84 ± 261.454
SecondaryPercentage of Subject Who Remain Opioid Free.

Opioid free is defined as no opioid rescue medication was recorded for the timepoint displayed and onwards.

Time frame:
Surgical Closure to Day 30
Reported as:
Count of participants · Participants
Percentage of Subject Who Remain Opioid Free.
ParticipantsATX-101 1000 mgATX-101 1500 mgBupivacaine HydrochlorideSaline Placebo
Surgical Closure - Day 303610
Day 4 - Day 30121360
Day 5 - Day 30131560
Day 8 - Day 301417101
Day 15 - Day 301722161
Day 22 - Day 302427231
SecondaryTotal Post-surgical Use of Rescue Opioid Medications.

Total post-surgical use of rescue opioid medications (days).

Time frame:
Surgical Closure to Day 30, Opioid consumption is summarized descriptively every 24-hour period through Day 30
Reported as:
Mean · IV Morphine Milligram Equivalent (MME)
Total Post-surgical Use of Rescue Opioid Medications.
IV Morphine Milligram Equivalent (MME)ATX-101 1000 mgATX-101 1500 mgBupivacaine HydrochlorideSaline Placebo
Surgical Closure - Hour 24 (Day 1)63.153 ± 62.683358.399 ± 47.171243.283 ± 29.0513119.800 ± 58.1316
Hour 24 (Day 1) - Hour 48 (Day 2)44.628 ± 40.083533.566 ± 29.960836.804 ± 30.9289107.250 ± 50.5486
Hour 48 (Day 2) - Hour 72 (Day 3)30.500 ± 25.124425.795 ± 18.925132.550 ± 21.333840.000 ± 8.6603
Hour 72 (Day 3) - Day 424.044 ± 22.306223.783 ± 19.750425.369 ± 16.946535.000 ± 22.9129
Day 4 - Day 526.733 ± 26.005422.214 ± 18.127423.853 ± 20.035737.500 ± 19.8431
Day 5 - Day 625.000 ± 21.505824.063 ± 22.509225.067 ± 25.093340.000 ± 22.9129
Day 6 - Day 727.206 ± 21.881818.923 ± 13.272526.225 ± 21.120927.500 ± 15.6125
Day 7 - Day 819.147 ± 13.750916.000 ± 9.703328.219 ± 20.873418.750 ± 9.9216
Day 8 - Day 919.147 ± 10.308921.042 ± 17.014019.833 ± 13.736925.000 ± 17.3205
Day 9 - Day 1020.176 ± 13.476815.045 ± 8.326020.192 ± 13.824120.000 ± 11.4564
Day 10 - Day 1120.214 ± 12.421617.591 ± 10.965421.100 ± 13.882412.750 ± 3.1820
Day 11 - Day 1216.417 ± 12.720114.208 ± 11.336715.875 ± 8.077015.000 ± 7.5000
Day 12 - Day 1316.071 ± 10.728915.900 ± 9.176721.567 ± 14.935412.500 ± 4.3301
Day 13 - Day 1413.571 ± 7.119514.591 ± 7.545919.500 ± 12.850430.000 ± NA
Day 14 - Day 1520.200 ± 17.229313.850 ± 9.614914.091 ± 6.545315.000 ± 10.6066
Day 15 - Day 1617.045 ± 11.609217.571 ± 7.705112.321 ± 8.560515.000 ± 10.6066
Day 16 - Day 1714.821 ± 7.811711.167 ± 4.130718.682 ± 10.694115.000 ± 10.6066
Day 17 - Day 1814.271 ± 8.733112.700 ± 5.735910.232 ± 8.815415.000 ± 10.6066
Day 18 - Day 1917.981 ± 20.511312.500 ± 6.123711.411 ± 9.17447.500 ± 0.0000
Day 19 - Day 2017.550 ± 14.29937.875 ± 0.750014.722 ± 10.112211.250 ± 5.3033
Day 20 - Day 2117.778 ± 15.178313.000 ± 9.548112.563 ± 5.28097.500 ± 0.0000
Day 21 - Day 2217.273 ± 14.326711.083 ± 5.508310.972 ± 4.91247.500 ± 0.0000
Day 22 - Day 2319.861 ± 17.00699.750 ± 3.570713.750 ± 5.645818.333 ± 18.7639
Day 23 - Day 2416.750 ± 14.132311.000 ± 4.168311.250 ± 4.107931.667 ± 41.8579
Day 24 - Day 2513.906 ± 14.751513.400 ± 11.087213.750 ± 3.061918.333 ± 18.7639
Day 25 - Day 2618.750 ± 14.270512.357 ± 9.072513.500 ± 3.35417.500 ± 0.0000
Day 26 - Day 279.844 ± 6.13979.857 ± 3.869911.250 ± 7.500023.750 ± 22.9810
Day 27 - Day 2818.500 ± 20.661012.700 ± 6.996410.000 ± 4.3301—
Day 28 - Day 2917.917 ± 19.197411.700 ± 5.92246.563 ± 1.875020.000 ± NA
Day 29 - Day 3047.500 ± NA16.000 ± NA7.500 ± 0.0000—
SecondaryTime to First Rescue Opioid Medication.

Time to first postsurgical use of rescue opioid medication (days).

Time frame:
Surgical Closure to Day 30
Reported as:
Mean · Days
Time to First Rescue Opioid Medication.
DaysATX-101 1000 mgATX-101 1500 mgBupivacaine HydrochlorideSaline Placebo
Time to First Rescue Opioid Medication.0.478 ± 0.98620.257 ± 0.25710.491 ± 0.69250.223 ± 0.0820

Adverse events

Collected over Day 56. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ATX-101 1000 mg0/37 (0%)3/37 (8.1%)30/37 (81.1%)
ATX-101 1500 mg0/37 (0%)4/37 (10.8%)25/37 (67.6%)
Bupivacaine Hydrochloride0/34 (0%)2/34 (5.9%)28/34 (82.4%)
Saline Placebo0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventATX-101 1000 mgATX-101 1500 mgBupivacaine HydrochlorideSaline Placebo
HaemarthrosisMusculoskeletal and connective tissue disorders0/370/371/340/4
Pulmonary embolismVascular disorders0/371/371/340/4
Atrial fibrillationCardiac disorders1/370/370/340/4
DiarrhoeaGastrointestinal disorders0/371/370/340/4
Duodenal ulcerGastrointestinal disorders1/370/370/340/4
Liver injuryHepatobiliary disorders0/371/370/340/4
Incision site dischargeInjury, poisoning and procedural complications1/370/370/340/4
Hepatic enzyme increasedInvestigations0/371/370/340/4
DeliriumPsychiatric disorders0/371/370/340/4
Most frequent other events
Showing 10 of 11
Most frequent other events
EventATX-101 1000 mgATX-101 1500 mgBupivacaine HydrochlorideSaline Placebo
NauseaGastrointestinal disorders11/3710/379/342/4
ConstipationGastrointestinal disorders5/374/379/341/4
Joint swellingMusculoskeletal and connective tissue disorders1/372/374/341/4
Pain in extremityMusculoskeletal and connective tissue disorders2/372/371/341/4
DizzinessNervous system disorders3/376/370/340/4
Procedural painInjury, poisoning and procedural complications2/374/375/340/4
ContusionInjury, poisoning and procedural complications3/372/374/340/4
VomitingGastrointestinal disorders3/370/374/340/4
ArthralgiaMusculoskeletal and connective tissue disorders4/371/372/340/4
DiarrhoeaGastrointestinal disorders3/372/371/340/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ATX-101 1000 mgATX-101 1500 mgBupivacaine HydrochlorideSaline PlaceboTotal
<=18 years00000
Between 18 and 65 years151514246
>=65 years222220266
Age, Continuous
Age, Continuous(years)ATX-101 1000 mgATX-101 1500 mgBupivacaine HydrochlorideSaline PlaceboTotal
Mean68.2 ± 8.1268.3 ± 6.8967.5 ± 7.6263.0 ± 12.3867.8 ± 7.69
Sex: Female, Male
Sex: Female, Male(Participants)ATX-101 1000 mgATX-101 1500 mgBupivacaine HydrochlorideSaline PlaceboTotal
Female201922263
Male171812249
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ATX-101 1000 mgATX-101 1500 mgBupivacaine HydrochlorideSaline PlaceboTotal
American Indian or Alaska Native01001
Asian03104
Black or African American01102
Native Hawaiian or Other Pacific Islander00000
White3531324102
Other21003
Unknown00000
Not Reported00000
Region of Enrollment
Region of Enrollment(participants)ATX-101 1000 mgATX-101 1500 mgBupivacaine HydrochlorideSaline PlaceboTotal
Canada767020
United Kingdom101013033
Australia202114459
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m2)ATX-101 1000 mgATX-101 1500 mgBupivacaine HydrochlorideSaline PlaceboTotal
Mean30.39 ± 4.47331.20 ± 5.13133.01 ± 5.18529.58 ± 1.43131.42 ± 4.934
08

Study locations

13 sites
  • Prince of Wales Private Hospital
    Sydney, New South Wales 2031, Australia
  • John Flynn Private Hospital
    Tugun, Queensland 4224, Australia
  • Royal Adelaide Hospital / PARC Clinical Research
    Adelaide, South Australia 5000, Australia
  • St Andrew's Private Hospital
    Adelaide, South Australia 5000, Australia
  • The Avenue Private Hospital
    Windsor, Victoria 3181, Australia
  • Durham Bone and Joint Specialists
    Ajax, Ontario L1S 7K7, Canada
  • London Health Sciences Centre - University Hospital
    London, Ontario C9 124, Canada
  • Department of Trauma and Orthopaedic Surgery, Addenbrooke's Hospital
    Cambridge, Cambridgeshire CB2 0QQ, United Kingdom
  • Southampton General Hospital
    Southampton, Hampshire SO16 6YD, United Kingdom
  • Royal National Orthopaedic Hospital
    Stanmore, Middlesex HA7 4LP, United Kingdom
  • Nottingham Elective Orthopaedic Service, Nottingham University Hospitals
    Nottingham, Nottinghamshire NG5 1PB, United Kingdom
  • Robert Jones & Agnes Hunt Orthopaedic Hospital
    Oswestry, Shropshire SY10 7AG, United Kingdom
  • Chapel Allerton Hospital C/O The Leeds Teaching Hospitals NHS Trust
    Leeds, West Yorkshire LS7 4SA, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Jan 2024, 19 months.

Results were first posted in Aug 2025, 1 year 6 months after primary completion. A results delay was requested in Dec 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2022
First posted
Mar 2, 2022
StartActual
Jun 7, 2022
Primary completionActual
Jan 15, 2024
CompletionActual
Jan 15, 2024
Results delay requested
Dec 23, 2024
Results first posted
Aug 14, 2025
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05260008
Lead sponsor
Allay Therapeutics, Inc.
Responsible party
Sponsor
First posted
Mar 2, 2022
Start date
Jun 7, 2022
Primary completion
Jan 15, 2024
Completion
Jan 15, 2024
Results posted
Aug 14, 2025
Last update
Aug 14, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: APIM-containing Peptide ATX-101

Start the discussion